MRD-guided treatment cessation in multiple myeloma

The prognostic value of MRD in multiple myeloma & MRD-guided therapyПодробнее

MRD-guided treatment in multiple myelomaПодробнее

The importance of MRD in multiple myeloma in guiding treatment decisions & access to therapiesПодробнее

The benefit of using MRD to guide treatment decisions in multiple myelomaПодробнее

Should MRD Guide Myeloma Treatment? A Debate. | Rahul Banerjee, MD and Sridevi Rajeeve, MD |IMS 2024Подробнее

Are we ready for MRD-guided therapy in multiple myeloma?Подробнее

MRD-guided high-dose carfilzomib treatment for multiple myelomaПодробнее

MASTER subgroup analysis: quadruplet induction, autoSCT & treatment cessation in NDMM patients ≥70Подробнее

Using MRD to guide treatment decisions during SCT in multiple myelomaПодробнее

MRD2STOP: Can multimodal MRD negativity guide discontinuation of maintenance treatment in myeloma?Подробнее

Approaching MRD in Multiple MyelomaПодробнее

MRD-guided therapy for myelomaПодробнее

Where does MRD belong as a tool in myeloma?Подробнее

MRD-guided therapy in multiple myelomaПодробнее

What does it mean when a myeloma patient is MRD negative?Подробнее

How does minimal residual disease (MRD) testing affect treatment decisions?Подробнее

Maintenance Cessation in MRD Negative Patients | Neha Korde, MD | ASH 2022Подробнее

Using MRD to guide treatment decisions in the clinicПодробнее

After ASH 2022, are we closer to using MRD-guided treatment decisions in MM?Подробнее